Deb Doherty

Rep. Thomas Massie is calling on Americans to contact Congress this week and demand glyphosate immunity be stripped from the Farm Bill. “People this week should be calling their congressmen and their senators and saying, ‘Take the glyphosate immunity out of the farm bill.’” “If nothing else, ask to allow Chellie Pingree and Thomas Massie to have a vote on their amendment.” “So that everybody can go on record as to whether they support immunity for a German company or not.”

Farm Bill as is - is a no go!

On Monday, Representative Chellie Pingree stood on the steps of the Supreme Court and named what is actually happening in Congress right now. Bayer has 53 lobbyists working Capitol Hill and is spending millions to jam a liability shield into the Farm Bill, language that would strip Americans of their right to sue when a product gives them cancer. Pingree fought to have it removed in committee. Every single Republican and one Democrat voted to keep it in. Across the street from that rally, the House Rules Committee was deciding the same day whether the Pingree-Massie Protect Our Health Amendment would even be allowed a floor vote. She has been an organic farmer in Maine since the 1970s and has been fighting this fight long before MAHA existed. Her message on Monday? No one can claim to support making America healthy again while voting to protect the companies spraying toxic chemicals on American farmland. Cancer is not a partisan issue, and any Farm Bill that shields chemical companies over farm families is not pro-farmer, not pro-health, and not pro-America. Bayer has the money. The people showed up Monday in Washington to make clear that is not enough. @chelliepingree

Your gut bacteria can pivot from bodyguards to house-eaters in less than a week. 🚩 When you skip the fiber, you starve the beneficial microbes that keep your immune system in check. Here is why your gut bacteria need fiber (and why you should bookmark this for your next grocery run): 🧵 1. The Microbial "Happy Dance" Beneficial bacteria, like Bifidobacteria, thrive on prebiotic fiber. When they eat fiber, they produce Short-Chain Fatty Acids (SCFAs) like butyrate. The Benefit: Butyrate fuels the cells of your gut lining, reduces inflammation, and may even improve insulin sensitivity. 2. The "Starvation" Shift When you switch to a low-fiber, highly processed diet, these beneficial bugs begin to starve. In their absence, opportunistic microbes, the ones linked to systemic inflammation and chronic disease, start to take over. 3. Speed is the Factor This isn't a slow process. Research shows your microbial profile can shift significantly in as little as 3 to 5 days of dietary change. Your gut is incredibly responsive to what you do (or don't) put on your plate. How to Feed the "Good Guys" ✅ Resistant Starch: Raw green bananas or cooled potatoes. ✅ Soluble Fiber: Oats, beans, and berries. ✅ Prebiotic Powerhouses: Onions, garlic, and leeks. Fiber isn't just "roughage"; it's a protective shield for your intestinal integrity. Manage your gut ecosystem with the right lifestyle habits. #Microbiome #GutHealth

Alex Clark: "We are asking one simple question: Why does Bayer deserve protection but American families and farmers don’t? A country that can’t protect its children from corporate poison is not a free country, it’s a captured one."

"It turns out that for 45 years we've been treating cancer incorrectly, we've been administering chemotherapy and radiation as the fundamental principle to cure cancer"... "And it turns out we're eliminating a cell that has evolved over 450 million years, called the natural killer cell"... "This cell… is the cell that protects us from cancer"... "My greatest fear now is turbo cancers...For the first time, I'm seeing young children with pancreatic cancer and colon cancer"... "Two children passed away… due to metastatic pancreatic cancer"... "What's happening?"...

🚨KENNEDY: “We shouldn’t be talking about Glyphosate, we should be talking about Roundup” ROGAN: “We need poison to make food”.. it's “so crazy... other countries don’t use Glyphosate and feed their population” Vani Hari: “Monsanto will be arguing for the right to poison us” President Trump doesn’t want China to control the food supply and thinks Glyphosate is a National Security Issue.. but RFK Jr. says 77% of American children can’t qualify for Military service.. because of Chronic Disease. Glyphosate is a pervasive pesticide that HHS Sec. Robert F Kennedy Jr. also says causes cancer... further exacerbating the Chronic Disease Epidemic. President Trump still has a National Security Issue, even if he saves Bayer (Monsanto) and gives them immunity from the damage their product causes.

Here at Rules committee meeting at The Capitol demanding corporate capture ends here and to pass the protect our health amendment by @chelliepingree @RepThomasMassie - are you for people @CongressmanGT or poison?!? @RepChipRoy @RepRalphNorman @RepLangworthy

Kelly Ryerson: “But if your product is safe, then you don't need immunity.” “And if your business depends on immunity, the problem is not the lawsuits.” “The problem is the product.”

🚨 “WE’RE DONE PRETENDING THIS IS NORMAL” Vani Hari Just Slammed Trump on Behalf of MAHA, Says the Administration is Protecting Bayer/Monsanto: “You cannot tell Americans to eat “real food” while protecting the cancer-causing chemicals sprayed on it. You cannot stand with families and side with one of the most evil corporations in the world. Let's be honest. We wouldn't be here right now if President Trump didn't sign that executive order. We wouldn't be here right now if they weren't inside this building arguing on Monsanto's behalf. We wouldn't be here right now if they didn't submit that amicus brief and that recommendation to the Supreme Court to look at this case when they've lost all over this country. You cannot stand with families and do that.” 👏

As far back as 2019, Richard Pazdur, then head of OCE at FDA, recognized the importance of lymphocyte count in progression free survival and overall survival in lung cancer. I just discovered this paper today, just as I recently discovered the 2007 NCI workshop report showing the importance of T cell growth factor. He concludes that "baseline LDH level and dNLR are important prognostic biomarkers irrespective of treatment modality for patients with mNSCLC" meaning that whether the patient receives radiation, chemo, or checkpoint inhibitors, the level of lymphocyte count (ALC) is the critical biomarker for outcomes regardless of treatment modality. The Saudi FDA recognized this immediately and on that basis approved Anktiva for the treatment of 2nd line lung cancer who relapsed following standard of care. Pazdur further states "As further prospective clinical trial information is collected, the role of the LIPI score can be better defined." Stay tuned.

Dr. Patrick Soon-Shiong: "It turns out that for 45 years we've been treating cancer incorrectly, we've been administering chemotherapy and radiation as the fundamental principle to cure cancer" "And it turns out we're eliminating a cell that has evolved over 450 million years, called the natural killer cell" "This cell… is the cell that protects us from cancer"

$IBRX Paradigm Shift in Cancer Care: Immune Restoration is Gaining Global Momentum Dr. Patrick Soon-Shiong: ‘Cancer isn’t the disease — it’s the symptom. The real disease is the collapse of your immune system’ (via lymphopenia depleting NK & T cells). He argues we should focus on rebuilding and supporting immune competence so the body can fight back effectively — powering ImmunityBio’s Anktiva (IL-15 superagonist for NK & T cell restoration). Just days ago (April 21, 2026), ImmunityBio announced ANKTIVA® is now commercially available in Saudi Arabia for bladder and lung cancer patients — accelerated approval for metastatic NSCLC with checkpoint inhibitors (first globally). Market entry achieved within two months of the MENA partnership. This builds on Saudi SFDA approvals, EU conditional marketing authorization (now in 33+ countries), UK MHRA approval, Macau as the first in Asia, and growing momentum across Asia including Japan through regional collaborations and expanding access to immune restoration therapies. Strategic MOU with Saudi Ministry of Investment (MISA), King Faisal Specialist Hospital & Research Centre (KFSHRC), and King Abdullah International Medical Research Center (KAIMRC) advancing the Cancer BioShield platform across the Middle East as ‘Immunotherapy 2.0’. Dr. Robert Redfield (former CDC Director): ‘Patrick is onto something profound… We have to abandon the old “destroy the patient to kill the cancer” model. Chemo & radiation wipe out the immune system. IL-15 rebuilds & supercharges it.’ Wellness and root-cause perspectives: Luke Coutinho: ‘Cancer is a symptom of a dysfunctional immune system and an indication that your body is out of balance.’ Chris Wark: ‘Cancer is the symptom of a sick body, not the cause. You aren’t sick because you have cancer. You have cancer because you are sick.’ This ties directly into MAHA’s strong emphasis on immune health, addressing chronic disease root causes, prevention, and rethinking treatment paradigms. Alignment from President Trump and RFK Jr. on accelerating innovative health solutions. Dr. Soon-Shiong has been a vocal supporter of these reform efforts, including MAHA Media Hub discussions and viewing the administration’s health focus as a historic opportunity. Supporting doctors posting lately: Dr. Aditya Bardia (UCLA) recently presented breakthrough data at AACR 2026 showing post-COVID lymphopenia linked to poorer prognosis, poorer treatment response, and up to 2.46x higher recurrence risk in breast cancer (even early stages 1-3) — reinforcing the immune collapse angle. Longtime collaborators Dr. James Gulley and Dr. Jeffrey Schlom (NCI) continue advancing cancer vaccine + Anktiva trials with strong tumor-specific T cell results. FDA previously approved Anktiva for BCG-unresponsive NMIBC, affirming the powerful IL-15 mechanism (ranked #1 potential cancer-curing molecule since 2007 by top NCI/NIH experts). Broader immunotherapy (checkpoint inhibitors, CAR-T, NK therapies) advancing globally in powerful combinations, with promising durable responses when immunity is strengthened. Exciting times with ImmunityBio (NASDAQ: IBRX) leading the charge on immune restoration! Dr. Soon-Shiong’s recent posts highlight the growing drumbeat of lymphopenia evidence and the Saudi launch success. What specific international results, trials, patient outcomes from Saudi/EU/Asia (including Japan momentum), or MAHA-aligned efforts stand out most to you? Could this be the breakthrough we’ve been waiting for? @DrPatrickSoonShiong @ImmunityBio @RobertRedfield @lukecoutinho @chrisbeatcancer @KFSHRC @KAIMRC @SaudiMOH @ChrisCuomo @realDonaldTrump @RobertKennedyJr 🚀 💪

🚨World Renowned Cancer Biologist Professor Thomas Seyfried reveals new Ivermectin studies underway for cancer He also presents a new paper on how anti parasitics like Mebendazole and Fenbendazole work Dr. Dominic D’Agostino from University of South Florida mentions he's just received a grant proposal from team DESANTIS, who is investing in Ivermectin and Metabolic Therapies for cancer. D’Agostino - "My Blood Levels of Ivermectin are off the charts" SEYFRIED - "we were planning to do ivermectin studies, but it became such a hot political topic I didn't want to get into it.. but we have a paper in Bio Archives now... it's under review for a bigger journal, on mebendazole the parasite medication" "Knowing that mebendazole targets glycolysis and glutaminolysis pathways... [and] when you put it under calorie restricted ketosis it works really really well" "We haven't tested ivermectin yet but we we have that in the plan" Stunningly, Seyfried mentions how Nutritional Ketosis is the key that unlocks the power of Anti Parasitics. Like, share and follow my page for more updates on this matter.

$IBRX An early-stage breast cancer patient. She gets chemotherapy and pembrolizumab. She achieves pathologic complete response. Her scan is clean. Her oncologist tells her that her cancer is gone. Then she gets COVID. Her oncologist is watching her tumor markers, her imaging, her symptoms. Her oncologist is not watching her absolute lymphocyte count. Eighteen months later, the cancer comes back in her bones. That population is real. 28,742 patients. UCLA and Mount Sinai. AACR late-breaker, April 21. They diagrammed what drives breast cancer recurrence: NK cell depletion, T cell exhaustion, lymphocytes lost. One FDA-approved drug hits every target on the diagram. Its name isn't in the paper. THE SENTENCE The abstract ends with one line, dropped cleanly, without drama: "Lymphopenia is a potentially modifiable risk factor that warrants prospective study as a therapeutic target." That is a clinical trial protocol written by an 8-author academic team, published in a peer-reviewed AACR late-breaker, calling for a trial of lymphopenia-correcting therapy in breast cancer patients. They did not name which drug. There is one. WHO WROTE IT Authors on the poster: Lisa Shiliang Zhang, Eric Yang, Alexis LeVee, Sonia Hui, Gavin Hui, Marla Lipsyc-Sharf, Carlos Cordon-Cardo, and Aditya Bardia. Lead author: Zhang, UCLA. Senior author: Bardia, UCLA (a renowned breast cancer oncologist). Mount Sinai co-author: Cordon-Cardo, Chairman of Pathology at Icahn School of Medicine. AACR Annual Meeting 2026. Abstract 5418. Cancer Research 2026;86(7 Suppl). (AACR Journals) WHAT THEY STUDIED A multi-institutional retrospective cohort of breast cancer patients from two academic medical centers. Initial cohort: 36,496. After exclusions: 28,742 in the analysis cohort. Stratified by COVID-19 exposure, by lymphopenia status, and by stage. All patients Stage 1 through Stage 3 (curative-intent early breast cancer, not metastatic). Outcomes measured: local recurrence, distant recurrence, and event-free survival. Overlaid onto the clinical data: bulk RNA sequencing from rapid-autopsy studies, used to anchor the mechanism. This is ~80 times larger than the SABCS triple-negative paper PSS surfaced April 20. Same research team, vastly bigger cohort, and now covering every histologic subtype of early-stage breast cancer rather than TNBC alone. THE FINDING THAT MATTERS Read these carefully. Among all COVID-positive breast cancer patients in the cohort: - Local recurrence: HR 2.47 (p<0.001) - Distant recurrence: HR 1.50 (p<0.001) Now split the distant-recurrence average by lymphocyte status: - COVID with subsequent lymphopenia: HR 2.46 (p=0.009) - COVID without lymphopenia: HR 1.11 (not significant, p=0.68) The distant recurrence risk from COVID is not distributed evenly across all COVID-positive patients. It is concentrated entirely in the subgroup whose lymphocyte counts dropped afterward. The subgroup whose lymphocyte counts held firm did not suffer a meaningful increase in distant recurrence. Fix the lymphopenia, fix the risk. In epidemiology, that is a mediation finding. The causal variable has been isolated. And unlike most mediation papers, this one names a variable that is measurable (free, on every CBC), modifiable (lymphocytes can be restored), and already addressable by an existing drug. THE DIAGRAM The paper's Figure 4 walks through the proposed mechanism, arrow by arrow: Local breast disease → COVID-19 infection → four parallel downstream effects: 1. Cytokine storm and inflammation (elevated IL-6, IL-1β, TNFα, IFNγ, IL-10) 2. Lymphopenia and apoptosis (depletion of B cells, CD4+ T cells, CD8+ T cells, and natural killer cells) 3. p53 dysregulation in cancer cells 4. T cell and NK cell exhaustion (elevated PD-1, NKG2A, TIM-3) All four pathways converge on one endpoint: decreased immune surveillance. And from there, distant recurrence. This is the cleanest unified framework the breast cancer field has for how post-treatment recurrence works immunologically, rather than just through cancer biology alone. THE MIRROR IMAGE Now read ImmunityBio's mechanism language, from the April 21 Saudi launch press release: "At the core of our strategy is the Cancer BioShield platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 superagonist." And the Saudi NSCLC accelerated-approval label, quoted verbatim: "Approved under accelerated approval based on the increase of ALC associated with overall survival in single arm study." Place the two pictures side by side. Bardia's diagram lists: low NK cells, exhausted T cells, low CD8+ and CD4+ T cells, elevated PD-1 and NKG2A and TIM-3. ANKTIVA's FDA-labeled mechanism raises NK cells, CD8+ cytotoxic T cells, and memory T cells via IL-15 receptor agonism. Published clinical data across ImmunityBio's program have shown corresponding restoration of absolute lymphocyte counts. Mirror image. Bardia's team drew the problem. The FDA label already describes the tool. The academic team was not required to name a drug class. By calling for a trial of lymphopenia-correcting therapy, they named one anyway. THE DRUMBEAT @DrPatrick numbered his posts on this. #1 (April 20): The UCLA / City of Hope SABCS 2025 paper on early TNBC. N=372. pCR 45.9% vs 63.0% in lymphopenic vs normal arms. (AACR PS4-10-26) #2 (April 21): The 28,742-patient cohort study above. All early-stage breast cancer. Post-COVID framing. Mediation analysis. Mechanism diagram. (AACR 5418) #3 (April 22): Same 372 TNBC cohort tracked through treatment. Lymphopenia rises from 9.9% at baseline to 38.7% pre-surgery. In the subgroup whose lymphocytes crash during chemo: 14.9% complete response vs 82% for those who hold firm. p=0.034. (AACR Abstract C040) Three beats, three days, same senior author, same UCLA / Mount Sinai research program. PSS is explicitly numbering them in sequence. The program is still active. WHAT THIS IS ABOUT Remember the woman from the opening. Complete response. Clean scan. Then COVID. Then eighteen months later, the cancer in her bones. She is one of a population. Approximately 310,000 early breast cancer diagnoses per year in the United States. About 2.3 million worldwide, the vast majority early-stage and curative-intent. A substantial subset experience treatment-related lymphopenia, post-COVID lymphopenia, or both. Some meaningful fraction of their recurrences, this paper argues, is driven by a lab value nobody was watching and that can be raised by a drug already FDA-approved for a different indication. One drug. Already on the shelf. Already reimbursed by Medicare under its own J-code. Already shipping on three continents. Already funded by a sovereign factory in Riyadh. Just not approved for her. Not in the country where it was invented and is manufactured. WHAT SHOULD HAVE BEEN A PRESS RELEASE FIVE TIMES OVER ImmunityBio's Saudi commercial launch landed April 21. The Saudi label is the first in any jurisdiction to cite "increase of ALC associated with overall survival" as the accelerated approval basis for non-small cell lung cancer. Saudi regulators just accepted ALC as a surrogate endpoint for survival. Bardia's team just made ALC a predictor of breast cancer recurrence. The same biomarker. The same drug class. Two countries, two tumor types, on the public record within the same day. Also on April 21, RFK Jr., the US Health Secretary, said on camera: "China is now eating our lunch... They went from running 3% of clinical trials to running 30%... we are fast-tracking approvals now in our country at record levels." PSS reposted that clip to his feed. Five signals. One week. The frame is no longer emerging. The frame is here. THE CLOSE Her scans came back clean. Then she caught COVID. Her lymphocyte count quietly dropped. Nobody was watching it. Eighteen months later, the cancer was in her bones. The drug that could have held the line was already FDA-approved when she started treatment. Just not for her.

Dr. Robert Malone...“Fauci stopped the U.S. Army from researching the benefits of vitamin D for soldiers because it wasn’t vaccine based.” “We are coming off of literally decades of intentional suppression of the use & benefits of vitamin D.” “Tony Fauci directly suppressed the interest of the U.S. Army in advancing vitamin D research.” “They had discovered that adding vitamin D… made a huge difference in respiratory infections in troops.” “But Tony’s comment when approached by the lead scientist on this project was that, we treat infectious disease with vaccines, not with nutritional supplements.”

🚨Ron Johnson drops the HAMMER at RFK's Senate Hearing: “They HID the myocarditis signal… They HID the stroke signal… They MASKED adverse events in VAERS.” “There are a BUNCH of people involved in this COVER-UP who still work within HHS, CDC, and FDA.” Subpoenas are coming. @SenRonJohnson

Something happened in a Massachusetts federal courtroom that I can't stop thinking about, even now, even knowing what ICAN was able to do after, even knowing the charter got amended and we moved the ball. I can't just let it go. Think about this: The American Academy of Pediatrics sued Robert Kennedy Jr. and HHS. And what they were suing over, the thing they argued constituted harm, was the possibility that doctors might get to have a conversation with their patients about vaccines. That's what they wanted stopped. Shared decision-making. The radical idea that a pediatrician and a parent might sit down together and talk about what's right for that specific child. Now, the AAP takes money from pharmaceutical companies. That's documented. So when they go to federal court to protect the full 54-vaccine mandate, you have to ask who they're really representing in that room. It is not the pediatricians. It is not the children. The judge agreed with them. And then he went further, declaring that Kennedy's advisory committee was flawed, specifically because it didn't have enough members with financial ties to the vaccine industry. He said, in effect, that the people who profit from the schedule have a right to vote on the schedule. An activist judge handed pharma a structural guarantee, a legal argument that you cannot reform the advisory process without their seat at the table. We got the charter amended, and that matters. But what was said out loud in that courtroom, I don't think we should forget what that judge was willing to put his name on.

Dr. Patrick Soon-Shiong dropped a cancer paradigm shift that could change everything: “Cancer isn’t the disease — it’s the symptom. The real disease is the collapse of your immune system.” Instead of destroying the body with aggressive treatments, he says we should focus on rebuilding and supporting the immune system so it can actually fight back. No single magic bullet, but the science is finally moving fast — and he’s calling for more clinical trials to turn this new understanding into real results. This one idea flips the entire approach to cancer treatment on its head. What do you think — could shifting from attacking cancer to strengthening the immune system be the breakthrough we’ve been waiting for, or is it still too early to tell?

The evidence generated by UCLA is compelling. This presentation entitled, "Sustained lymphopenia during neoadjuvant chemo-immunotherapy is associated with worse outcomes in early triple-negative breast cancer" was presented at ASCO-IO (Feb 2026). #3 ASCO-IO (Feb 2026): Early Stage Triple Negative Breast Cancer (TNBC) In a 372 patient study, the data shows that only 15% of patients with early stage TNBC have a pathological complete response (pCR) when the ALC is less than 1,000 cells while 82% of patients with NK and T cells (ALC greater than 1,000 cells) have a complete response after therapy. This difference is stark and significant (p=0.034). Dr Bardia states:”Sustained lymphopenia and the development of relative lymphopenia during neoadjuvant chemo-immunotherapy may reflect impaired anti-tumor immune responses in patients with early-stage TNBC, highlighting need for intervention therapeutics in this setting“ Conclusion: Treatment-induced lymphopenia can impact anti-tumor immune responses and disease outcomes in patients with early-stage TNBC, highlighting the need for therapeutic interventions in this setting aacrjournals.org/cancerimmunolr…